XBI: STATE STREET(R) SPDR(R) S&P(R) BIOTECH ETF
Share-split context: A forward split was recorded on Sep 11, 2015 with coefficient 3.000003. A forward split turns each old share into multiple new shares and lowers the quoted price per share proportionally. Proportional ownership is unchanged at the split moment, so the split itself creates neither a gain nor a loss. The price-return figures in this report are already split-adjusted.
What this ETF is trying to do
The STATE STREET(R) SPDR(R) S&P(R) BIOTECH ETF (XBI) is an exchange-traded fund that invests in biotechnology companies. It holds a variety of stocks in this sector. As of October 8, 2026, the fund has 166 total holdings.
Top Holdings
The fund's portfolio can change over time. Some of its largest holdings include:
• Moderna Inc: 1.95%
• Twist Bioscience Corp: 1.84%
• Natera Inc: 1.72%
• Biogen Inc: 1.57%
• AbbVie Inc: 1.54%
What the numbers show
The current price of XBI is $150.23. Because this ETF has a history of share splits, we look at split-adjusted returns to see how it has performed.
• Price Return: This measures only the change in the share price. The one-year price return is approximately 44.90%, and the three-year price return is approximately 107.99%.
• Total Return: This reflects the overall return, including distributions. The one-year total return is approximately 45.50%, and the three-year total return is approximately 109.27%.
• Year-to-Date (YTD): The YTD price return is 23.21%, while the YTD total return is approximately 23.33%.
This ETF has a history of a "forward split" from September 11, 2015. In a forward split, each old share becomes multiple new shares, and the price per share drops proportionally. This change does not create a gain or a loss; it simply changes the number of shares an investor owns.
Income and distribution explanation
XBI provides cash distributions to investors, but they happen irregularly. Over the last 12 months, there were 2 payouts. The distribution yield is approximately 0.36%.
It is important for beginners to know that a distribution yield is not the same as a total return. While distributions provide cash income, they do not guarantee that the original investment value (the principal) will stay the same.
NAV erosion explanation
"NAV erosion" happens when the internal value of a fund's assets declines over time. StockValueFinder uses an erosion-risk score to measure this. XBI has an erosion score of 100, and the label states "No price erosion detected." The erosion severity is rated as "good," and there is no severe erosion-risk flag.
Pros
• Strong split-adjusted price and total returns over the last one and three years.
• No detected price erosion according to the erosion-risk score.
• Diversified across 166 different holdings.
Cons
• Very low distribution yield.
• Distributions are irregular and less frequent.
Beginner takeaway
XBI focuses on the biotech industry. While it has shown significant price growth over the last three years, it is not designed for investors seeking high regular income. Always remember that a high yield alone can be misleading, as it does not account for whether the share price is rising or falling.
Top Holdings
Structured portfolio holdings supplied by the ETF data provider. These figures are not generated by the AI article.
| # | Holding | Ticker | Weight |
|---|---|---|---|
| 1 | MODERNA INC | MRNA | 1.95% |
| 2 | TWIST BIOSCIENCE CORP | TWST | 1.84% |
| 3 | NATERA INC | NTRA | 1.72% |
| 4 | BIOGEN INC | BIIB | 1.57% |
| 5 | ABBVIE INC | ABBV | 1.54% |
| 6 | HALOZYME THERAPEUTICS INC | HALO | 1.52% |
| 7 | AMGEN INC | AMGN | 1.51% |
| 8 | GILEAD SCIENCES INC | GILD | 1.51% |
| 9 | CRISPR THERAPEUTICS AG | CRSP | 1.49% |
| 10 | TG THERAPEUTICS INC | TGTX | 1.49% |